Navigation Links
Gene expression test identifies low-risk thyroid nodules
Date:6/25/2012

PHILADELPHIA - A new test can be used to identify low-risk thyroid nodules, reducing unnecessary surgeries for people with thyroid nodules that have indeterminate results after biopsy. The results of the multi-center trial, which includes researchers from the Perelman School of Medicine at the University of Pennsylvania, appear online in the New England Journal of Medicine.

Ultrasound-guided fine-needle aspiration biopsies (FNA) accurately identify 62-85 percent of thyroid nodules as benign. For those deemed malignant or unclassifiable, surgery is currently required. However, about 20-35 percent of nodules have inconclusive results after FNA. This novel test classifies genes from the thyroid nodule tissue obtained through FNA.

"This test, currently available at Penn Medicine, can help us determine whether these nodules with indeterminate biopsy results are likely to be benign," said Susan Mandel, MD, MPH, professor of Medicine in Endocrinology, Diabetes and Metabolism in the Perelman School of Medicine at Penn."If so, patients may be able to avoid unnecessary surgeries and lifelong thyroid hormone replacement treatment."

In an accompanying NEJM editorial, J. Larry Jameson, MD, PhD, Dean of the Perelman School of Medicine and Executive Vice President for the Health System at the University of Pennsylvania, notes that the gene expression test is able to identify nodules at low risk of malignancy, making it possible to avoid approximately 25,000 thyroid surgeries per year. "In this era of focusing on high-quality outcomes at lower cost, this new gene expression classifier test is a welcome addition to the tools available for informed decision making about the management of thyroid nodules," writes Jameson.

The gene expression classifier was tested on 265 indeterminate thyroid nodules, and was able to correctly identify 92 percent of cases as suspicious. The test demonstrated a 85 - 95 percent negative predictive value, effectively ruling out a malignancy.

The Penn research team included Dr. Mandel, Zubair Baloch, MD, PhD, and Virginia A. LiVolsi, MD, both professors of Pathology and Laboratory Medicine. The investigation was funded by a research grant provided by Veracyte, Inc., the maker of the gene expression classifier.


'/>"/>

Contact: Kim Menard
kim.menard@uphs.upenn.edu
215-662-6183
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Changes in gene expression may help explain high blood pressure in pregnancy
2. Control of gene expression: Histone occupancy in your genome
3. Overexpression of proteins 14-3-3 related to chemotherapy resistance
4. New study identifies promising, achievable solutions to Nigerias childhood mortality crisis
5. Study identifies potential treatment for lethal childhood leukemia
6. New study identifies how information technology is used to solve global health challenges
7. Study identifies possible protective blood factors against Type 2 diabetes
8. Genetic test identifies eye cancer tumors likely to spread
9. 3-center study identifies main causes of unprofessional behavior among hospitalists
10. Global Energy Assessment identifies pathways to a sustainable energy future
11. Food elimination diet identifies causes of difficulty swallowing and swelling of the throat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... , ... Over $60 Billion is spent annually on products for our favorite ... review site for Toys, Tots, Pets & More (TTPM) announced the 15 winners of ... the Metropolitan Pavilion in New York City. , Chosen from a field of hundreds ...
(Date:5/2/2016)... , ... May 02, 2016 , ... Further establishing itself ... announce that the new WHIMZEES Variety Value Boxes were selected from over 1,000 entrants ... Showcase Award. , WHIMZEES natural dental chews for dogs are a favorite product ...
(Date:5/2/2016)... ... May 02, 2016 , ... The 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was ... made the cut. The WUGC is being held in London, England this year from June ... the men’s division, another gold in the women’s masters division, and a silver in the ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Sixth Annual Lifestyle Intervention ... Bellagio Hotel in Las Vegas, NV from October 17–19, 2016. The Nevada ... event. , This year’s conference will offer presentations featuring new treatment tracks, ...
(Date:5/2/2016)... ... , ... Dr. Jonathan Kulbersh of Carolina Facial Plastics isn’t surprised that Charlotte, NC, the city ... “ 5 US Cities with the Highest Plastic Rates .” The other cities that ... were calculated using a survey by RealSelf and combining that data with the ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Research and Markets has announced ... Market 2016-2020" report to their offering. ... The global plastic surgery products market is expected to ... 2016-2020. , ,The growing adoption of laser in aesthetics ... the market. Lasers are used to treat a broad ...
(Date:4/28/2016)... WARSAW, Ind., April 28, 2016 , Net ... a reported basis over the prior year period, and an ... basis , Diluted EPS for the first quarter were ... period, and $2.00 adjusted, an increase of 29.9% over the ... revenue and adjusted earnings guidance for 2016 Zimmer ...
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage ... gene-based immunotherapeutics and vaccines for the treatment of cancer & ... 3rd Annual Growth Capital Expo to be held ... Caesars Palace in Las Vegas, Nevada.  The Company presentation ... th by Dr. John N. Bonfiglio a ...
Breaking Medicine Technology: